TY - JOUR
T1 - SUMOylation occurs in acute kidney injury and plays a cytoprotective role
AU - Guo, Chunyuan
AU - Wei, Qingqing
AU - Su, Yunchao
AU - Dong, Zheng
N1 - Funding Information:
The study was supported in part by grants from the National Natural Science Foundation of China [ 81430017 ], National Basic Research Program of China 973 Program No. 2012CB517601 , National Institutes of Health ( DK058831 , DK087843 ), and Department of Veterans Administration (MERIT Review) of USA .
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - SUMOylation is a form of post-translational modification where small ubiquitin-like modifiers (SUMO) are covalently attached to target proteins to regulate their properties. SUMOylation has been demonstrated during cell stress and implicated in cellular stress response. However, it is largely unclear if SUMOylation contributes to the pathogenesis of kidney diseases, such as acute kidney injury (AKI). Here we have demonstrated a dynamic change of protein SUMOylation in ischemic and cisplatin nephrotoxic AKI in mice. In rat kidney proximal tubular cells (RPTC), cisplatin-induced SUMOylation was diminished by two antioxidants (N-acetylcysteine and dimethylurea), supporting a role of oxidative stress in the activation of SUMOylation. In addition, SUMOylation by SUMO-2/3, but not SUMO-1, was partially suppressed by pifithrin-alpha (a pharmacological inhibitor of p53), supporting a role of p53 in SUMOylation by SUMO-2/3. We further examined the role of SUMOylation during cisplatin treatment of RPTC by using ginkgolic acid (GA), a pharmacological inhibitor of SUMOylation. Pretreatment with GA suppressed SUMOylation and importantly, GA enhanced apoptosis during cisplatin incubation. Taken together, the results demonstrate the first evidence of SUMOylation in AKI and suggest that SUMOylation may play a cytoprotective role in kidney tubular cells.
AB - SUMOylation is a form of post-translational modification where small ubiquitin-like modifiers (SUMO) are covalently attached to target proteins to regulate their properties. SUMOylation has been demonstrated during cell stress and implicated in cellular stress response. However, it is largely unclear if SUMOylation contributes to the pathogenesis of kidney diseases, such as acute kidney injury (AKI). Here we have demonstrated a dynamic change of protein SUMOylation in ischemic and cisplatin nephrotoxic AKI in mice. In rat kidney proximal tubular cells (RPTC), cisplatin-induced SUMOylation was diminished by two antioxidants (N-acetylcysteine and dimethylurea), supporting a role of oxidative stress in the activation of SUMOylation. In addition, SUMOylation by SUMO-2/3, but not SUMO-1, was partially suppressed by pifithrin-alpha (a pharmacological inhibitor of p53), supporting a role of p53 in SUMOylation by SUMO-2/3. We further examined the role of SUMOylation during cisplatin treatment of RPTC by using ginkgolic acid (GA), a pharmacological inhibitor of SUMOylation. Pretreatment with GA suppressed SUMOylation and importantly, GA enhanced apoptosis during cisplatin incubation. Taken together, the results demonstrate the first evidence of SUMOylation in AKI and suggest that SUMOylation may play a cytoprotective role in kidney tubular cells.
KW - Apoptosis
KW - Cisplatin nephrotoxicity
KW - P53
KW - ROS
KW - Renal ischemia-reperfusion
KW - SUMOylation
UR - http://www.scopus.com/inward/record.url?scp=84920093315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920093315&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2014.12.013
DO - 10.1016/j.bbadis.2014.12.013
M3 - Article
C2 - 25533125
AN - SCOPUS:84920093315
SN - 0925-4439
VL - 1852
SP - 482
EP - 489
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 3
ER -